pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
RISING · news · pharmadog
← back to RISING
News mentioning RISING
268
stories
5h
Labor Department finalizes sweeping PBM disclosure rule
biopharma dive
17h
Opinion: Health care needs buyers willing to say no
stat
17h
Politicians have failed to tackle health care affordability. It’s now voters’ rallying cry
stat
22h
8 companies hiring in New York
biospace
1d
Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readout
biospace
1d
Genmab’s cancer bispecific delivers early OS win in ‘exceedingly positive’ Phase 3 readout
biospace
1d
Biogen set up for growth even without M&A but CEO won’t rule it out
biospace
1d
2026 IPO stock tracker: How newly public biotechs are performing
biospace
1d
STAT+: As Epic’s dominance grows, its iron grip is choking innovation in health technology
stat
1d
Biotechs going to market alone must learn to go global
biospace
2d
Parkinson’s-focused Aspen and bispecific biotech Bambusa both shoot for $134M IPOs
fiercebiotech
3d
STAT+: Nonprofit Bon Secours Mercy Health strikes $5.7 billion deal for surgery center chain
stat
3d
STAT+: HHS relaxes security, transparency rules for health record software used by hospitals
stat
3d
STAT+: GSK sees its return to cancer start to pay off
stat
3d
STAT+: Rising premiums, a sad Medicaid gathering, and a new fraud crackdown
stat
3d
Another autoimmune CAR-T death; Treasury zeroes in on China deals
biopharma dive
6d
STAT+: Up and down the ladder: The latest comings and goings
stat
6d
This week in charts: a big year for RNAi developers
biopharma dive
6d
US explores China biotech restrictions, exempts licensing deals
biospace
7d
Chutes & Ladders—Troubled CSL enlists GSK vet Deborah Waterhouse to lead
fiercebiotech
7d
Health insurance premiums jump 9%, and more Americans don’t have access to coverage
stat
7d
STAT+: Workers are paying 9% more for family health coverage this year, a higher jump than in the recent past
stat
9d
Lycia aims for $228M IPO to generate data on food allergy rival to Xolair
fiercebiotech
9d
Alnylam bulls and bears fight it out after business-shaking guidance cut
biospace
10d
China tightens grip on biotech platform ownership but foreign licensing deals still okay
biospace
13d
STAT+: Up and down the ladder: The latest comings and goings
stat
13d
OrbiMed raises two new life sciences funds worth $3B with one aiming for Asia
biospace
13d
iPSCs come of age, powering breakthroughs in the lab and clinic
biospace
13d
Opinion: Is Milton Friedman to blame for America’s health care woes?
stat
14d
Aligning drug discovery around patient benefit from the outset: Connecting human insights to better decisions
fiercebiotech
← prev
page 1 of 9
next →
